Sinew Pharma, Inc.(TW:6634)
NT$63.20+6.00 (+10.49%)
TW:6634
Sinew Pharma, Inc. financials statements
NT$63.20
At close:+6.00 (+10.49%)
Sinew Pharma, Inc. (6634) Ratios
Sinew Pharma, Inc. Ratios
TW:6634's free cash flow for Q2 2026 was NT$-53.34M. For the 2026 fiscal year, TW:6634's free cash flow was decreased by NT$-314.00K and operating cash flow was NT$-53.03M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 42.27 | 43.46 | 36.81 | 60.56 | 99.36 |
| Quick Ratio | 42.27 | 43.46 | 36.81 | 60.56 | 99.36 |
| Cash Ratio | 0.99 | 1.52 | 4.74 | 10.61 | 36.48 |
| Solvency Ratio | -2.87 | -4.16 | -3.57 | -4.10 | -4.32 |
| Operating Cash Flow Ratio | -3.74 | -3.90 | -3.35 | -4.03 | -3.79 |
| Short-Term Operating Cash Flow Coverage | -15.96 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 1.04B | NT$ 1.15B | NT$ 1.26B | NT$ 1.38B | NT$ 1.49B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.03 | 1.02 | 1.03 | 1.02 | 1.01 |
| Debt Service Coverage Ratio | -18.22 | -289.01 | -202.66 | -425.79 | -471.13 |
| Interest Coverage Ratio | -213.28 | -407.88 | -240.02 | -539.74 | -646.71 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.22 | 0.05 | 0.14 | 0.11 | 0.02 |
| Net Debt to EBITDA | 0.08 | 0.32 | 1.00 | 2.04 | 8.00 |
| Profitability Margins | |||||
| Gross Profit Margin | -41051.06% | 0.00% | 0.00% | 88.41% | 81.75% |
| EBIT Margin | -298140.43% | 0.00% | 0.00% | -42653.96% | -1467.80% |
| EBITDA Margin | -257010.64% | 0.00% | 0.00% | -35698.78% | -1104.27% |
| Operating Profit Margin | -298140.43% | 0.00% | 0.00% | -45252.44% | -1515.81% |
| Pretax Profit Margin | -263287.23% | 0.00% | 0.00% | -42737.80% | -1470.14% |
| Net Profit Margin | -263287.23% | 0.00% | 0.00% | -42737.80% | -1470.14% |
| Continuous Operations Profit Margin | -263287.23% | 0.00% | 0.00% | -42737.80% | -1470.14% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 88.31% | 89.05% | 91.77% | 94.44% | 96.99% |
| Return on Assets (ROA) | -10.97% | -12.26% | -12.54% | -9.43% | -5.78% |
| Return on Equity (ROE) | -11.34% | -12.56% | -12.91% | -9.61% | -5.84% |
| Return on Capital Employed (ROCE) | -12.71% | -14.08% | -14.02% | -10.14% | -6.02% |
| Return on Invested Capital (ROIC) | -12.65% | -14.05% | -13.96% | -10.12% | -6.01% |
| Return on Tangible Assets | -11.13% | -12.49% | -12.90% | -9.79% | -6.03% |
| Earnings Yield | -4.45% | -4.43% | -3.58% | -1.92% | -1.88% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.01 | 0.00 | 0.00 | 0.27 | 14.39 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.02 | 1.38 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Cash Conversion Cycle | 27569.15 | 0.00 | 0.00 | 1358.73 | 25.37 |
| Days of Sales Outstanding | 27569.15 | 0.00 | 0.00 | 1358.73 | 25.37 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 27569.15 | 0.00 | 0.00 | 1358.73 | 25.37 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.34 | -1.49 | -1.68 | -1.35 | -0.96 |
| Free Cash Flow Per Share | -1.37 | -1.51 | -1.78 | -1.44 | -1.06 |
| Dividend Paid and CapEx Coverage Ratio | -50.91 | -79.82 | -15.85 | -15.93 | -9.77 |
| Capital Expenditure Coverage Ratio | -50.91 | -79.82 | -15.85 | -15.93 | -9.77 |
| Operating Cash Flow Coverage Ratio | -6.27 | -37.62 | -12.72 | -12.43 | -54.43 |
| Operating Cash Flow to Sales Ratio | -2027.64 | 0.00 | 0.00 | -285.86 | -9.20 |
| Free Cash Flow Yield | -3.49% | -3.17% | -2.63% | -1.36% | -1.30% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -22.50 | -22.54 | -27.90 | -52.23 | -53.25 |
| Price-to-Sales (P/S) Ratio | 59183.97 | 0.00 | 0.00 | 22289.45 | 783.25 |
| Price-to-Book (P/B) Ratio | 2.55 | 2.83 | 3.60 | 5.01 | 3.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -28.63 | -31.57 | -38.00 | -73.37 | -77.22 |
| Price-to-Operating Cash Flow Ratio | -29.19 | -31.97 | -40.40 | -77.97 | -85.12 |
| Price-to-Earnings Growth (PEG) Ratio | 1.28 | 1.71 | -1.37 | -1.68 | 14.20 |
| Enterprise Value Multiple | -22.94 | -28.02 | -29.32 | -60.40 | -62.93 |
| Enterprise Value | 2.77B | 3.35B | 4.61B | 7.07B | 4.33B |
| EV to EBITDA | -22.94 | -28.02 | -29.32 | -60.40 | -62.93 |
| EV to Sales | 58969.82 | 0.00 | 0.00 | 21560.39 | 694.93 |
| EV to Free Cash Flow | -28.52 | -31.21 | -36.74 | -70.97 | -68.51 |
| EV to Operating Cash Flow | -29.08 | -31.60 | -39.06 | -75.42 | -75.52 |
| Tangible Book Value Per Share | 15.14 | 16.48 | 18.27 | 20.24 | 25.24 |
| Shareholders’ Equity Per Share | 15.36 | 16.79 | 18.82 | 21.05 | 26.37 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 |
| Net Income Per Share | -1.74 | -2.11 | -2.43 | -2.02 | -1.54 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.88 | 1.00 | 0.92 | 1.00 | 1.00 |
| Research & Development to Revenue | 1862.21 | 0.00 | 0.00 | 349.45 | 11.68 |
| SG&A to Revenue | 708.68 | 0.00 | 0.00 | 103.96 | 4.30 |
| Stock-Based Compensation to Revenue | 361.83 | 0.00 | 0.00 | 50.94 | 1.94 |
| Income Quality | 0.77 | 0.71 | 0.69 | 0.67 | 0.63 |
Currency in TWD
